vimarsana.com

Page 12 - ஆரோக்கியம் பராமரிப்பு செலவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BCBSA backs Lumiata s $14M round to boost COVID-19 risk management using AI

Jan 20, 2021 3:30pm The pandemic has brought once-in-a-century challenges to insurance underwriters when they had to predict patient risk for 2021 in the summer of 2020. (WrightStudios/Shutterstock) The COVID-19 pandemic has been a pivotal time for advances in artificial intelligence as organizations use the technology to drive research, find new treatments and analyze patient data. San Mateo, California-based Lumiata is ramping up its efforts to use AI to help identify underwriting risks during the crisis. The company just got a big infusion of cash to help fuel its work. Lumiata raised $14 million in a series B funding round backed by early-stage venture capital firm Defy.vc, venture capital fund AllegisNL Capital, Khosla Ventures and Blue Venture Fund, the venture capital arm of the Blue Cross Blue Shield Association.

Global $50+ Billion Healthcare Artificial Intelligence Market to 2027: Focus on Medical Imaging, Precision Medicine, & Patient Management

Dublin, Jan. 15, 2021 (GLOBE NEWSWIRE) The "Healthcare Artificial Intelligence Market - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The global healthcare artificial intelligence (AI) market is expected to grow at a CAGR of 41.4% from 2020 to 2027 to reach $51.3 billion by 2027. The growth in the healthcare artificial intelligence market is mainly attributed to the factors such as rising venture capital investment for artificial intelligence in healthcare sector, growing demand for personalized therapy, positive impact due to COVID-19, rising demand to reduce healthcare costs, and rise in volume and complexities in healthcare datasets. Moreover, the growing potential of AI based tools for treatment of chronic illness and its growing implementation in clinical trials provide growth opportunities for players operating in the healthcare artificial intelligence market. On the basis of product & services, the software s

Liz Weston: Start 2021 off strong with these money moves

Early Release - Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States - Volume 27, Number 1—January 2021 - Emerging Infectious Diseases journal

18) and untreated recreational water ( 19) in the United States, but the burden of disease from all water sources (drinking, recreational, environmental) and exposure routes (ingestion, contact, inhalation) has not been estimated. We present an estimate of the burden of waterborne disease in the United States that includes gastrointestinal, respiratory, and systemic disease; accounts for underdiagnosis; and includes all water sources and exposure routes. Methods We defined waterborne disease as disease in which water was the proximate vehicle for exposure to an infectious pathogen. Thus, diseases such as Legionnaires’ disease (typically transmitted via inhaled water droplets containing Legionella bacteria) were considered waterborne. In contrast, arboviral diseases like malaria, for which standing water can increase the population of mosquitoes that transmit the parasite that causes malaria, were not considered waterborne. Algal toxins and chemical exposures were not considere

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.